Eculizumab use in neuromyelitis optica spectrum disorders: real-world evidence from Germany and Austria

Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, Ozalp SH, Lohmann L, Giglhuber K, Haeussler V, Karenfort M, Hellwig K, Paul F, Bellmann-Strobl J, Otto C, Ruprecht K, Ziemssen T, Emmer A, Rothhammer V, Nickel F, Angstwurm K, Linker R, Laurent S, Warnke C, Jarius S, Kuhnke MK, Wildemann B, Wolff S, Seipelt M, Yalachkov Y, Retzlaff N, Zettl UK, Rommer P, Kowarik MC, Wickel J, Geis C, Huemmert MW, Trebst C, Senel M, Klotz L, Kleinschnitz C, Meuth SG, Aktas O, Berthele A, Ayzenberg I (2022)


Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: SAGE PUBLICATIONS LTD

City/Town: LONDON

Pages Range: 664-666

Conference Proceedings Title: MULTIPLE SCLEROSIS JOURNAL

Event location: Amsterdam NL

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Ringelstein, M., Asseyer, S., Lindenblatt, G., Fischer, K., Pul, R., Ozalp, S.-H.,... Ayzenberg, I. (2022). Eculizumab use in neuromyelitis optica spectrum disorders: real-world evidence from Germany and Austria. In MULTIPLE SCLEROSIS JOURNAL (pp. 664-666). Amsterdam, NL: LONDON: SAGE PUBLICATIONS LTD.

MLA:

Ringelstein, M., et al. "Eculizumab use in neuromyelitis optica spectrum disorders: real-world evidence from Germany and Austria." Proceedings of the 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam LONDON: SAGE PUBLICATIONS LTD, 2022. 664-666.

BibTeX: Download